Proteins involved in the growth response of prostate cancer cells to androgen were investigated by comparing the proteomes of LNCaP cells treated with vehicle or androgen. Whole-cell lysates were separated by twodimensional PAGE, and HPLC-MS/MS was used to identify androgen-regulated proteins. Prohibitin, a protein with cell-cycle regulatory activity, was shown to be downregulated by 50% following androgen stimulation. Western blot and reverse transcription-PCR experiments confirmed the result and showed that regulation occurs at the level of transcription. To determine the importance of prohibitin in androgen-stimulated growth, we used transient transfection to overexpress the protein and RNA interference to knock down the protein. Subsequent FACS analysis showed that cells with reduced levels of prohibitin showed a slight but reproducible increase in the percentage of population in cell cycle, while cells with increased prohibitin levels showed a clear reduction in the percentage entering cell cycle, following dihydrotestosterone stimulation, when compared to untransfected controls. Confocal microscopy showed localization of prohibitin in the nucleus as well as the mitochondria of LNCaP cells. It therefore seems that the regulation of prohibitin is a vital part of the cellular growth response to androgen stimulation in LNCaPs and prohibitin may have a nuclear regulatory role in cell-cycle progression.
Introduction
Prostate cancer is now the most commonly diagnosed cancer in Western males (Greenlee et al., 2001) . Prostate tumours are initially dependent on growth stimulation by circulating androgens (Koivisto et al., 1998) . The major circulating androgen is testosterone, which is converted to dihydrotestosterone (DHT) in prostate cells by the enzyme 5a-reductase. DHT is the major androgen in prostate growth and development. Androgen response is mediated by binding of DHT or other androgens to the androgen receptor (AR), a ligand-activated transcription factor. This then translocates to the nucleus, binds response elements in the promoters of target genes and activates transcription from these promoters, resulting in the production of proteins involved in mitosis and differentiation of the prostate (Koivisto et al., 1998) . Treatment for advanced prostate cancer primarily involves compounds that interfere with this signalling process, by blocking the production of circulating androgen and/or by inhibiting the AR itself (Grayhack et al., 1987) . It is now well documented that these treatments fail after prolonged use, and growth of the cancer then recurs (Koivisto et al., 1998) . Evidence suggests that this recurrence of growth is often facilitated by modification of the original androgen-responsive pathway in the cancer cells, either by AR amplification (Visakorpi et al., 1995) or mutations of the receptor that allow it to be activated by noncanonical ligands (Gottlieb et al., 1997) and frequently by the very anti-androgens used as treatment. When this adaptation occurs, the patient relapses and no effective further therapies are currently available.
New treatments that regulate the function of an androgen-regulated, growth-related protein would be an ideal second line of therapy. This would allow treatment with current therapies to be followed, after relapse, by therapy designed to uncouple the growth signal downstream from the AR. However, few bona fide targets of the AR have yet been identified. We used twodimensional polyacrylamide gel electrophoresis (2-DE) to determine which proteins are regulated following androgen stimulation in the androgen-responsive prostate cancer cell line LNCaP. This provides a nonbiased approach allowing visualization of a large number of cellular proteins. Regulation of the protein may be detected not only at the level of total amounts of protein but also that of protein modification, such as acetylation and phosphorylation. The 30 kDa protein prohibitin was identified as being downregulated over 50% by androgen treatment.
Prohibitin appears to have dual roles in the cell, being ubiquitously expressed in the mitochondria and also located in the nucleus of certain cell types (Thompson et al., 2001; Wang et al., 2002a) . Prohibitin was initially suspected to be a tumour suppressor gene, due to the ability of the mRNA to inhibit DNA synthesis and cell cycle (McClung et al., 1989) . Current data show two likely roles for the protein, firstly as a mitochondrial chaperone protein in a complex with BaP37/REA (Repressor of oEstrogen receptor Activity) (Coates et al., 1997) , and secondly as a regulator of cell cycle (Nuell et al., 1991) . The mitochondrial role of prohibitin appears to be as part of a 'holdase', tightly bound in a complex with REA, with 12-14 of these subunits forming a barrel-like structure (Steglich et al., 1999) . This structure protects mitochondrial proteins required for protein complexes from degradation by proteases until import of further cytoplasmic components has occurred (Coates et al., 1997) . It is possible that this mitochondrial function is regulated in response to cell growth, as prohibitin protein levels appear to increase in differentiated cells (Thompson et al., 2001) . It has also been suggested that prohibitin may protect against apoptosis at times of metabolic stress in both yeast and mammalian cells, a function possibly related to its localization in the mitochondria (Vander Heiden et al., 2002) . The cell-cycle function of prohibitin is less well understood and there is some dispute over the precise role of the protein (Coates et al., 2001) . Injection of the mRNA results in cell-cycle arrest in some cell types (McClung et al., 1989; Nuell et al., 1991) , and this may in part be due to the 3 0 untranslated region (3 0 UTR) of the mRNA (Jupe et al., 1996) . Even the localization of the protein is not clear, with some groups maintaining that the protein is purely mitochondrial (Coates et al., 2001) , and others demonstrating a secondary localization in the nucleus (Thompson et al., 2001; Wang et al., 2002b) . However, recent observations that prohibitin can interact with members of the E2F transcription factor family (Wang et al., 1999a) support the concept of a nuclear role in cell-cycle regulation. It has been demonstrated, using transfection assays, that prohibitin can reduce the amount of transcription mediated by E2F1 by interacting directly with E2F1 and also recruiting Rb, histone deacetylases and the corepressor NCoR (Wang et al., 2002b) . This complex may form an alternative to the Rb-mediated repression of E2F, as Rb and prohibitin appear to bind E2F at different sites on the E2F protein and recruit different corepressors, prohibitin apparently linking E2F to HDACs via NCoR (Wang et al., 2002a) . As the current literature suggests a cell-cycle role in other hormoneresponsive cells, possibly via the regulation of transcription and post-translational modification (Thompson et al., 2001) , and we saw changes in prohibitin expression in prostate cancer cells simulated to grow by androgen, we have investigated its function further, with an aim of understanding its role in the cell cycle and growth responses to androgen stimulation in prostate cells.
Results

Prohibitin is downregulated by androgen treatment
LNCaP total cell extract was separated by isoelectric focusing (IEF) and 12% SDS-PAGE. A protein feature of 30 kDa and pI 5.7 showed a decrease of 50% detectable protein in the cells exposed to 100 nM DHT for 16 h (Figure 1a and b) . This protein was identified as prohibitin using HPLC-MS/MS (Figure 1c) , and confirmation of this decrease was obtained by standard SDS-PAGE Western blotting using the commercially available antibody to prohibitin, again showing a significant decrease in protein levels of around 50% following 16 h DHT exposure (Figure 2a) . At 4 h exposure to the hormone, no significant change in the prohibitin protein level was detected. A 48 h exposure resulted in a decrease of prohibitin by around 30%. To confirm that this effect was indeed downstream of the AR signalling pathway, the cell line PC3 (an AR-negative In all, 12 tryptic peptides were sequenced, comprising 104-amino-acid residues (39% coverage). A typical spectrum, from which the sequence AAELLANSLATAGDGLLELR was deduced, is shown prostate cancer cell line), stably transfected with either empty vector or vector containing wild-type AR, was exposed to 100 nM DHT for 16 h. This exposure resulted in a decrease of prohibitin of around 30% in AR-positive cells, whereas exposure of the untransfected cell line did not cause any decrease in prohibitin. Using primers designed to the first exon of the prohibitin RNA, reverse transcription-PCR (RT-PCR) also showed a decrease of mRNA in the exposed LNCaP cells of 50% following 16 h exposure (Figure 2b ), while the control RT-PCR showed no reduction in the levels of ABL message. This demonstrates that regulation of prohibitin by DHT exposure is probably at the level of transcriptional control, although we cannot rule out a specific effect on prohibitin mRNA stability.
Prohibitin regulation occurs at concentrations of DHT that promote growth of LNCaP cells
The Western blot of prohibitin demonstrated a clear dose-response relationship between 16 h DHT exposure and prohibitin levels (Figure 3a and b), with maximum repression of prohibitin expression occurring at 10 and 100 nM DHT. At concentrations above 100 nM DHT, repression of prohibitin was not as pronounced, an effect mirrored at concentrations of less than 10 nM DHT. Exposure of LNCaP cells to 1, 10, 100 and 1000 nM DHT ( Figure 3c ) demonstrated increased growth of LNCaP cells after 48 h compared to control, as measured by sulphorhodamine B assay, with repression at 10 mM.
Prohibitin inhibits stimulation of growth by androgens in LNCaPs
LNCaP cells were cotransfected with spectrin-GFP and a prohibitin expression vector or empty vector at a 
Silencing of prohibitin using RNAi causes a small increase in cell-cycle entry in LNCaPs
Given the observed regulation of prohibitin in LNCaP cells in response to concentrations of DHT that cause cell growth, we next investigated the importance of prohibitin downregulation to the cell cycle. Two sets of small inhibitory RNA (siRNA) oligos were designed complementary to the mRNA for prohibitin, one to the main body of the mRNA in exon 1 (siPHB1) and a second to the 3 0 UTR of the mRNA (siPHB2). As a control, a commercially available random oligo of same length with no homology to known mammalian genes was used. Transfection for 48 h, followed by 72 h incubation in RPMI medium supplemented with charcoal-stripped serum, resulted in a knockdown of the prohibitin protein by siPHB2 of 80% as detected by Western blot compared to b-actin loading (Figure 5a ). No reduction in prohibitin protein was observed after transfection with control oligo (not shown) or siPHB1, so only siPHB2 was used in all further experiments.
FACS analysis of transfected cells reproducibly showed a small but consistent increase in cells entering cell cycle upon silencing of prohibitin (Table 1) , with a small but significant decrease in the G 0 /G 1 population being mirrored by an increase in the S/G 2 /M population. In all, 2% more cells above control values were detected in the S/G 2 /M phase following RNA interference (RNAi), compared with a 10% increase following DHT treatment. This proportional increase in cell cycling was verified using the more sensitive technique of BrdU incorporation (Figure 5b and c) , with the increase in DNA-replicating, BrdU-positive cells after siRNA treatment (average 1.2%) being roughly 20% of the increase seen in DHT-treated cells (average 6.2%).
Prohibitin is present in the mitochondria and the nucleus of LNCaP cells
One way in which prohibitin may be affecting cell cycle is by direct interaction with transcription factors in the nucleus. To establish if this was possible in LNCaPs, we used confocal microscopy to determine whether prohibitin was present in the nucleus. Dual staining of LNCaP cells with antibodies to prohibitin and cytochrome c, a mitochondrial marker (Figure 6 ), demonstrated colocalization of endogenous prohibitin and cytochrome c in the mitochondria of the cells, and the presence of prohibitin staining in the nucleus was also noted. Z-stacking analysis confirmed that this staining represented discrete localization of the prohibitin protein within the nucleus. 
Discussion
The AR signalling pathway is fundamental to the hormonal therapy of prostate cancer and is also implicated in the ultimate failure of that treatment. Greater knowledge of the pathway linking stimulation of the AR to cell growth is therefore vital in our drive to find new treatments for prostate cancer. In a study to find proteins regulated by exposure to androgens, we identified prohibitin, a protein with a possible role in cell-cycle control (McClung et al., 1989 ) that also shows sequence similarity to a known coregulator of the oestrogen receptor, REA (Nijtmans et al., 2002) .
The downregulation of prohibitin at the protein level after 16 h exposure to DHT was detected by 2-DE, and confirmed by immunoblotting. This regulation was absent at 4 h exposure and still present at 48 h, although not as strongly as at 16 h, suggesting an effect of desynchronization of the cell cycle or possibly degradation of the DHT in culture. The regulation of prohibitin levels in response to hormone stimulation has been reported in other cell types (Thompson et al., 1999 (Thompson et al., , 2001 Dixit et al., 2003) , and regulation of prohibitin in response to growth stimuli and cellular differentiation is well documented (Liu et al., 1994; Coates et al., 1997; Woodlock et al., 2001; Fellenberg et al., 2003) . In addition, another prostate cancer cell line (PC3) stably transfected with wild-type AR also demonstrated an androgen-dependent decrease in prohibitin of around 30%, at 16 h exposure to 100 nM DHT, and this effect was not seen in the parental AR-negative cells. This confirms that the effects of prohibitin are directly related to AR action following stimulation by DHT, corroborated by the dose-dependent regulation of prohibitin caused by varying the concentration of DHT added to LNCaP cells. Although PC3 cells are AR-negative, androgen-insensitive cells, we were not surprised to see prohibitin expression in these cells, since the mitochondrial role of prohibitin has been demonstrated in cells with no hormone sensitivity and appears to be a fairly ubiquitous role, and further our confocal microscopy demonstrated that the majority of prohibitin even in LNCaP cells is mitochondrial. LNCaPs exposed to 100 nM DHT for 16 h also showed a reduction of prohibitin mRNA, indicating that the control of prohibitin protein levels in the cell is at least partially at the level of transcription. Although no canonical direct repeat androgen response elements (AREs) have been identified in the 5 0 regulatory region or first exon of the prohibitin gene, it has recently been shown that a wide variation of sequences may act as AREs (Verrijdt et al., 2003) , so direct regulation of the prohibitin promoter is a possibility.
Maximum repression of prohibitin occurred between 10 and 1000 nM DHT exposure, corresponding to the maximum growth increase observed in LNCaP cells exposed to DHT. This indicates that prohibitin protein has a negative effect on cell cycle in prostate epithelial cells. To determine the effect of increasing prohibitin levels, we transfected LNCaP cells with a prohibitin expression vector. FACS analysis showed that while increased expression of prohibitin did not have a significant effect on cell cycle in the absence of androgen, the cells were not capable of entering cell cycle upon stimulation with DHT. Prohibitin downregulation therefore appears to be a vital part of the sequence of events necessary for androgen stimulation of growth. As cell cycle per se was not affected by prohibitin overexpression, it appears that the cell-cycle effects of prohibitin may be solely related to the androgen-stimulated growth pathway. This suggests that prohibitin is part of a regulatory system that is present only in some cell types and requires hormone stimulation for its action. Hormone regulation of prohibitin has been documented in other cell types, and other laboratories have shown that prohibitin is capable of interacting with and inhibiting transcription by E2F in a breast cancer cell line, in a manner independent of the Rb protein (Wang et al., 1999a, b) . It is therefore possible that the role of prohibitin in LNCaP cells is to repress E2F activity and thus the expression of genes required for hormone-stimulated growth. Upon stimulation with hormone, downregulation of prohibitin protein and subsequent de-repression of E2F activity would allow transcriptional activation of those genes required for growth that are not directly under the control of AREs. The results of the RNAi experiments indicate that removal of prohibitin results in a small but reproducible increase in the cell population entering the cell-cycle phase. Although this increase is small, it is significant, especially in the light of the observation that only 15% of the cells enter the cell cycle following optimal DHT stimulation and prohibitin is unlikely to be the only cell-cycle regulator targeted by androgen to mediate cell-cycle entry. The fact that silencing of prohibitin partially mimics the effects of androgen stimulation, together with the observation that overexpression of prohibitin inhibits DHT stimulation of growth, supports our hypothesis that prohibitin is a major effector of androgen-regulated growth.
Prohibitin has long been known to localize to the mitochondria (Ikonen et al., 1995; Coates et al., 2001 ), but nuclear localization has also somewhat controversially been reported for various cell types (Wang et al., 1999a; Thompson et al., 2001 ). Nuclear prohibitin is reported chiefly in cells that are responsive to steroid hormones (Thompson et al., 1999 (Thompson et al., , 2001 Wang et al., 1999a; Dixit et al., 2003) , in agreement with an additional nuclear, cell-cycle regulatory role in these cells as well as that of mitochondrial chaperone.
In conclusion, it appears that prohibitin is an important target of androgens in prostate epithelial cells, regulated at the level of transcription and mediating androgen signalling through its effects on cell cycle. The nuclear localization and inhibitory effect of prohibitin on DHT-stimulated growth indicate that prohibitin has a major role to play in the repression of growth in unstimulated cells, possibly via E2F-mediated gene activation. This role appears to be specifically hormone related and may be distinct from the mitochondrial functions of prohibitin.
Materials and methods
Cell culture and treatments
The LNCaP prostate cancer cell line was obtained from the American Type Culture Collection and cultured at 371C, 5% CO 2 RPMI medium (Gibco) supplemented with 2 mM Lglutamine, 100 U/ml penicillin, 100 mg/ml streptomycin and 10% foetal bovine serum. PC3 cells transfected with an empty vector or wild-type AR (Peterziel et al., 1999) , were cultured as above with the addition of 4 mg/ml geneticin (Life Technologies). DHT (Sigma) was resuspended in ethanol, diluted to 1000 Â working strength (100 mM) in ethanol and stored at À201C until use. Flasks (25 cm 2 ) of cells were transferred to phenol red-free RPMI supplemented with 2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin and 10% charcoal-stripped foetal bovine serum for 24 h (unless otherwise stated) before exposure to androgen or ethanol. DHT or ethanol was added to spent medium from concurrently seeded flasks, mixed by inversion and added to the flasks. Cells were incubated as above for 4 or 16 h, then placed on ice and washed twice in 330 mM sucrose before lysis in IEF buffer.
Two-dimensional gel electrophoresis
2-DE was performed using immobilized pH gradient (IPG) strips (Amersham Biosciences) of pH range 3-10 (linear). The solubilized protein sample was applied to the strips during gel rehydration, according to the manufacturer's instructions. The samples were diluted with rehydration solution containing 8 M urea, 0.5% CHAPS, 0.2% DTT and 0.2% pharmalyte (pH 3-10) prior to loading, and for analytical gels total protein loaded was 250 mg in 450 ml, and for preparative gels 3 mg in 450 ml. The strips were focused at 0.05 mA/IPG strip for 60 kVh at 201C. After IEF, the strips were equilibrated in 1.5 M Tris pH 8.8 buffer containing 6 M urea, 30% glycerol, 2% SDS and 0.01% bromophenol blue, with the addition of 1% DTT for 15 min, followed by the same buffer with the addition of 4.8% iodoacetamide for 15 min. SDS-PAGE was performed using 12% T, 2.6% C separating polyacrylamide gels without a stacking gel, using the Iso-Dalt system (Amersham Biosciences). The second-dimension separation was carried out overnight at 20 mA/gel, 151C. Five samples were prepared as per experimental condition.
Protein visualization
Gels were fixed in a methanol, acetic acid and water solution (4 : 5 : 1 v/v/v) overnight prior to silver staining. Analytical gels were stained using the Owl silver stain kit (OWL Separation Systems Inc.), while preparative gels were stained using a modified mass spectrometry-compatible kit (Plus-One, Amersham Biosciences), modified according to Yan et al. (2000) .
Densitometry and gel image analysis
Silver-stained gels were scanned using a Biorad GS-710 calibrated imaging densitometer and analytical images were analysed using PDQuest v6.2.1 (Biorad) (Krauss et al., 1990; Corbett et al., 1994) . After detection of spots, the gels were aligned, landmarked and matched. Gels were then placed into the appropriate experimental class and differential analysis was performed. The Student's t-test was used to detect all spots that differed significantly between the control and exposed groups (Po0.05); all significantly different spots were then checked manually to eliminate any artefactual differences due to gel pattern distortions and inappropriately matched or badly detected spots.
Tandem mass spectrometry
In-gel digestion with trypsin was performed according to published methods (Jeno et al., 1995; Shevchenko et al., 1996; Wilm et al., 1996) modified for use with a robotic digestion system (Investigator ProGest, Genomic Solutions) (Wait et al., 2001) . Silver-stained gel pieces were first washed with 30 ml of 15 mM potassium ferricyanide/50 mM sodium thiosulphate (Gharahdaghi et al., 1999) , followed by successive rinses with deionized water, 50 mM ammonium hydrogen carbonate buffer and acetonitrile. Cysteine residues were reduced with DTT and derivatized by treatment with iodoacetamide. After further washing with ammonium hydrogen carbonate buffer, the gel pieces were again dehydrated with acetonitrile and dried at 601C, prior to addition of modified trypsin (Promega; 10 ml at 6.5 ng/ml in 25 mM ammonium hydrogen carbonate). Digestion proceeded for 8 h at 371C and products were recovered by sequential extractions with 25 mM ammonium hydrogen carbonate, 5% formic acid and acetonitrile. The pooled extracts were lyophilized and then redissolved in 0.1% formic acid for mass spectrometry. Tandem electrospray mass spectra were recorded using a Q-Tof hybrid quadrupole/orthogonal acceleration time-of-flight spectrometer (Micromass) interfaced to a Micromass CapLC capillary chromatograph. Samples were dissolved in 0.1% aqueous formic acid, and 6 ml injected onto a Pepmap C18 column (300 mm Â 0.5 cm; LC Packings), and washed for 3 min with 0.1% aqueous formic acid (with the stream select valve diverting the column effluent to waste). The flow rate was then reduced to 1 ml/min, the stream select valve was switched to the data acquisition position and the peptides were eluted into the mass spectrometer with an acetonitrile/0.1% formic acid gradient (5-70% acetonitrile over 20 min). The capillary voltage was set to 3500 V, and data-dependent MS/MS acquisitions were performed on precursors with charge states of 2, 3 or 4 over a survey mass range 540-1000. Known trypsin autolysis products and keratin-derived precursor ions were automatically excluded. The collision voltage was varied between 18 and 45 V depending on the charge and mass of the precursor. Product ion spectra were charge-state de-encrypted and deisotoped with a maximum entropy algorithm (MaxEnt 3, Micromass). Proteins were identified by correlation of uninterpreted tandem mass spectra to entries in SwissProt/ TREMBL, using ProteinLynx Global Server (Version 1, Micromass). One missed cleavage per peptide was allowed, and an initial mass tolerance of 50 ppm was used in all searches. Cysteines were assumed to be carbamidomethylated, but other potential modifications were not considered in the first pass search. If this approach failed, amino-acid sequences were deduced manually from the charge-state de-encrypted spectra (Wait et al., 2002) , and were used as queries for searches using BLAST (Altschul et al., 1997) and FASTS (Mackey et al., 2002) .
Western blot analysis
Cells were lysed in 2-DE lysis buffer and the protein concentration was determined by modified Bradford assay (Weekes et al., 1999) . In all, 50 mg of protein was loaded onto a 12% SDS polyacrylamide gel and electrophoretically transferred onto a nitrocellulose membrane (Transblot, Biorad). Blocking was carried out overnight in PBS with 5% nonfat milk and incubated with mouse anti-human prohibitin primary antibody (AbCam Ltd) at 1 : 5000 and mouse anti-human bactin antibody at 1 : 3000 for 1 h. After washing, detection was carried out using the alkaline phosphatase-conjugated antimouse IgG diluted to 1 : 5000, incubating for 1 h followed by further washes and incubation with the substrate for ECF TM (Amersham Biosciences) as per the manufacturer's instructions. Visualization was carried out using the fluorescence detection mode of the Typhoon phosphorimager (Amersham Biosciences).
Reverse transcription-PCR
Total RNA samples were prepared using trizol reagent (Gibco BRL) and quantified by measuring the absorbance at 260 nm. For RT-PCR, mRNA was isolated from the total RNA obtained, using the oligotex mRNA kit (Qiagen) according to the manufacturer's instructions. In all, 0.5 mg of sample was used for the RT reaction (Invitrogen) and 2 ml of this reaction was used in a PCR mix using Taq Gold (Applied Biosystems) and the primer pairs 5 0 -ctg cct tat ata atg tgg atg ctg-3 0 and 5 0 -gct ctc tct ggg tga tta gtt ctc-3 0 ; 5 0 -cgt ggg tac aga aac caa tta tct-3 0 and 5 0 -ctc tct ctg gct gat tag ttc tcc-3 0 , giving product sizes of 360 and 257 bp, respectively. Loading control PCR reactions were carried out using primers to the ABL cDNA as described previously (Slade et al., 1999) .
RNA interference
siRNA oligonucleotide duplexes were designed to exon 1 (5 0 -aac ucu gcc uua uau aau gug-3 0 ) and the 3 0 UTR (5 0 -aac aca gcc uuc cuu cug cuc-3 0 ) of the mRNA for prohibitin, and manufactured by MWG-Biotech AG. As a control, a random oligo sequence of 21 nucleotides was used (Qiagen) that has no homology to known mammalian genes. Transfection was carried out using oligofectamine (Invitrogen) according to the manufacturer's instructions, for 48 h in phenol red-free RPMI supplemented with 2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin and 10% charcoal-stripped foetal bovine serum. Following transfection as previously described, the medium was replaced and hormone treatment was carried out.
Sulphorhodomine assay of cell culture growth
To determine cell number following DHT treatment, the sulphorhodamine B assay was used (Skehan et al., 1990) . Cells were plated into 96-well plates at a density of 10 4 cells/well, medium was changed to phenol red-free, stripped serum medium for 48 h and subsequently hormone or carrier molecule added for 48 h. Eight samples were measured per concentration and the experiment was repeated three times.
Transfection of LNCaP cells with prohibitin
The following primers were used to amplify the prohibitin cDNA fragment from IMAGE clone 3010198, obtained from the HGMP-RC: Fwd 5 0 -taggaattccccgggatggctgccaaagtg-3 0 and Rev 5 0 -taattggatcctcactggggcagctggag-3 0 . The product obtained was then cloned into pSG5 expression vector using EcoR1/BamH1 restriction site. LNCaP cells were transfected with 2 mg spectrin-GFP and 18 mg of empty PSG5 (control) or pSG5-prohibitin using Fugene 6 transfection reagent (Roche), as per the manufacturer's instructions. Cells were incubated for 48 h in transfection reagent in stripped serum medium, before being dosed with hormone for 48 h.
Cell-cycle analysis
Cell-cycle analysis was performed by propidium iodide staining with or without bromodeoxyuridine (BrdU) staining. At 30 min before harvesting cells, 10 mM BrdU (Sigma) was added to the medium. Cells were then trypsinized, washed twice in PBS and fixed overnight at 41C in 70% ethanol. The cells were then incubated with 2 M HCl, followed by 0.5% Triton X-100 for 30min at room temperature, and then with a 1:3 dilution of fluorescein isothiocyanate (FITC)-conjugated anti-BrdU antibody (BD Biosciences) for 30 min. Between each treatment, cells were washed with PBS. Cells were then incubated with 5 mg/ml propidium iodide and 50 mg/ml RNase A in PBS for 1 h at room temperature. FACS analysis was carried out using a BecktonDickinson FACS Calibur machine using linear scale representation of forward and side scatter during flow analysis. Samples were prepared in triplicate after 48 h and analysed using CellQuest-Pro software. A total of 10 000 events were measured per sample.
Immunofluorescence and confocal microscopy
LNCaP cells were grown on sterile glass coverslips in 24-well plates to 30% confluence in RPMI media before being washed three times in PBS. Cells were fixed in methanol at À201C for 10 min. Coverslips were washed a further three times in PBS and treated with 10% whole goat serum and 10% whole rabbit serum (Dako Cytomation) for 30 min. Antibodies to prohibitin and sheep anti-human cytochrome c (1 : 100 dilution) were applied in 10% whole goat serum, 10% whole rabbit serum for 1 h and coverslips were washed three times in PBS. In all, 10% whole goat and rabbit serum was applied to the coverslips for a further 15 min prior to incubating with either an FITC isomer I or tetramethylrhodamine isothyocyanate (TRITC)-conjugated secondary antibody (Sigma) in the dark for 1 h. Cells were washed five times in PBS, mounted on glass slides with Vectorshield containing dapi (Vector Laboratories Inc.) and visualized on a Zeiss Meta 512 confocal microscope.
